ERBB2 and gastric carcinoma: In a previous study, we employed human gastric carcinoma cell line NCI-N87 with high HER2 expressions to generate trastuzumab-resistant NCI-N87/TR cell lines via stepwise exposure to increasing doses of trastuzumab [18].